On April 14, 2020, Yiling Pharmaceutical announced that Yiling Pharmaceutical and its subsidiary Beijing Yiling Pharmaceutical had received the approval document of drug supplement application concerning the application for new indications of Lianhua Qing
Astellas Pharma and Ironwood Pharmaceuticals announced approval has been obtained in Japan for the guanylate cyclase-C receptor agonist Linzess Tablets 0.25 mg (linaclotide) for the additional indication of chronic constipation.